The European Medicines Agency Accepts For Review GSK's Marketing Authorization Application For Linerixibat For Cholestatic Pruritus In Patients With Primary Biliary Cholangitis

Benzinga · 06/23 10:34
  • If approved, linerixibat could address high unmet medical need of patients living with cholestatic pruritus (relentless itch) and related sleep interference
  • Submission based on data from positive GLISTEN phase III trial